April 17, 2008

BrainCells Inc. Expands Series B Financing to $50 Million

April 17, 2008

BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety

March 10, 2008

BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing

September 27, 2007

BrainCells Inc., Taisho Pharmaceutical Co., Ltd. Sign Licensing Agreement for Novel CNS Program

May 30, 2007

BrainCells Names Seth D. Goldblum VP, Business Development

March 27, 2007

BrainCells and Lundbeck Form CNS Drug Research Collaboration

October 23, 2006

BrainCells and Organon to Collaborate in Discovery and Development of CNS Drugs

August 10, 2006

BrainCells In-Licenses Clinical-Stage CNS Compound From Mitsubishi Pharma

October 18, 2005

BrainCells Inc. Appoints James A. Schoeneck Chief Executive Officer

July 14, 2005

BrainCells Inc. Announces $17.7 Million Series A Financing